CTSO Cytosorbents Corp - 8-K

Item
3.01.   Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 1, 2026, CytoSorbents Corporation, a Delaware
corporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff
(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,
or until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued
listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with
Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to September 28, 2026, the bid price of the Company’s common stock, par
value $0.001 per share (the “Common Stock”), closes at $1.00 per share or more for a minimum of 10 consecutive trading days,
the Company will regain compliance with the Minimum Bid Price Requirement. The Extension Notice has no immediate effect on the listing
of the Common Stock on Nasdaq and does not affect the Company’s reporting requirements with the Securities and Exchange Commission
(the “SEC”).

As previously disclosed on its Current Report on
Form 8-K filed with the SEC on October 3, 2025, the Company received a letter on October 2, 2025, from the Staff indicating that, based
upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with
the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until March
31, 2026, to regain compliance with the Minimum Bid Price Requirement.

The Company intends to continue actively monitoring
the bid price for its Common Stock between now and September 28, 2026, and to continue considering available options to resolve the deficiency
and regain compliance with the Minimum Bid Price Requirement. These options include, but are not limited to, effecting a reverse stock
split, if necessary. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the
additional 180-day compliance period or that the Company’s Common Stock will not be delisted from Nasdaq.